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OBJECTIVES This work was undertaken to define the intrinsic cardiac risk of the patient population
referred for dobutamine stress perfusion imaging and to determine whether dobutamine
technetium-99m (99mTc)-sestamibi single-photon emission computed tomography (SPECT)
imaging is capable of risk stratification in this population.
BACKGROUND In animal models, dobutamine attenuates the myocardial uptake of 99mTc-sestamibi resulting
in underestimation of coronary stenoses. Therefore, we hypothesized that the prognostic
value of dobutamine stress 99mTc-sestamibi SPECT myocardial perfusion imaging might be
impaired, owing to reduced detection of coronary stenoses.
METHODS We reviewed the clinical outcome of 308 patients (166 women, 142 men) who underwent
dobutamine stress SPECT 99mTc-sestamibi imaging at our institution from September 1992
through December 1996.
RESULTS During an average follow-up of 1.9  1.1 years, there were 33 hard cardiac events (18
myocardial infarctions [MI] and 15 cardiac deaths) corresponding to an annual cardiac event
rate of 5.8%/year, which is significantly higher than the event rate for patients referred for
exercise SPECT imaging at our institution (2.2%/year). Event rates were higher after an
abnormal dobutamine 99mTc-sestamibi SPECT study (10.0%/year) than after a normal study
(2.3%/year) (p  0.01), even after adjusting for clinical variables. In the subgroup (n  29)
with dobutamine-induced ST-segment depression and abnormal SPECT imaging, the
prognosis was poor, with annual cardiac death and nonfatal MI rates of 7.9% and 13.2%,
respectively.
CONCLUSIONS Patients referred for dobutamine perfusion imaging are a high-risk population, and dobut-
amine stress 99mTc-sestamibi SPECT imaging is capable of risk stratification in these
patients. (J Am Coll Cardiol 2001;38:1511–7) © 2001 by the American College of
Cardiology
The prognostic value of technetium-99m (99mTc)-sestamibi
single-photon emission computed tomography (SPECT)
myocardial perfusion imaging has been firmly established,
although most studies to date have employed exercise (1–8)
or vasodilator stressors (7–11). For patients with contrain-
dications to exercise and vasodilator stressors, dobutamine
stress is frequently substituted under the assumption that
the prognostic value of dobutamine 99mTc-sestamibi
SPECT imaging should be comparable. However, there are
no studies addressing the prognostic value of dobutamine
99mTc-sestamibi SPECT imaging in this highly selected
patient population. All of the available studies employed
liberal criteria for the use of dobutamine and, therefore,
included many patients who would have been eligible for
exercise (12) or vasodilator stress (13,14).
In the canine model of coronary artery stenosis, dobut-
amine stress attenuates the myocardial uptake of 99mTc-
sestamibi (15,16), resulting in a significant underestimation
of the dobutamine-induced myocardial blood flow hetero-
geneity on 99mTc-sestamibi perfusion images. In light of
these findings, we hypothesized that the prognostic value of
dobutamine 99mTc-sestamibi SPECT imaging might be
inferior to that of exercise and vasodilator stressors, owing to
reduced detection of coronary artery stenoses.
Therefore, the objectives of this study were to define the
intrinsic cardiac risk of the patient population referred for
dobutamine perfusion imaging and to determine whether
dobutamine 99mTc-sestamibi SPECT imaging is capable of
risk stratification in this population.
METHODS
Patient population. Between September 1992 and De-
cember 1996, 359 consecutive patients were referred to the
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University of Virginia for dobutamine myocardial perfusion
imaging. Forty-one patients were excluded from this study
because planar imaging was employed with 99mTc-sestamibi
(n  37) or thallium-201 (n  14). The remaining 308
patients who underwent dobutamine 99mTc-sestamibi
SPECT imaging comprised the study population (Table 1).
We reserve dobutamine stress for patients who have con-
traindications to both treadmill exercise and vasodilator
stress agents (obstructive lung disease and/or recent use of
methylxanthines). Compared with patients referred for
exercise 99mTc-sestamibi SPECT imaging at our institution
(1), patients referred for dobutamine stress were signifi-
cantly older (62  11 years vs. 58  12 years, p  0.001),
more obese (194  50 lbs vs. 181  39 lbs, p  0.01) and
shorter in height (66  4 in vs. 67  4 in, p  0.01). The
prevalence of prior myocardial infarction (MI) (31% vs.
27%) and female gender (54% vs. 50%) was comparable in
patients referred for dobutamine and exercise, respectively
(1).
Dobutamine stress protocol. The dobutamine stress vari-
ables are summarized in Table 2. Dobutamine was infused
in 3-min increments of 5, 10, 20, 30 and 40 g/kg/min.
Atropine was not used to augment heart rate. Chest pain
developed during dobutamine infusion in 80 patients (26%),
and 52 patients (17%) developed ST-segment depression as
defined by standard criteria. Eight patients (3%) developed
nonsustained ventricular tachycardia during dobutamine
infusion, but no sustained arrhythmias or serious complica-
tions were observed.
Myocardial perfusion imaging protocol. In 98% of pa-
tients, a single-day rest-stress 99mTc-sestamibi imaging
protocol was used, with weight-adjusted doses of 8 to 10
mCi of 99mTc-sestamibi at rest and 25 to 30 mCi at peak
stress. In 2% of patients, a separate-day protocol was used,
with 25 to 30 mCi 99mTc-sestamibi for both the rest and
stress images. Images were acquired at least 60 min after
99mTc-sestamibi injection.
Image acquisition and interpretation. Technetium-99m-
sestamibi images were acquired using a Prism 3000 triple-
headed gamma camera (Picker, Cleveland, Ohio) or a
Sophy DS-7 single-headed gamma camera (Sopha Medical,
Buc, France). Our methods for image acquisition and
quantification have been previously described (17,18). Stud-
ies were interpreted clinically by one of five experienced
observers using visual and quantitative perfusion data. In
179 patients (58%), the quantitative analysis included an
automatic comparison of regional 99mTc-sestamibi activity
to a gender-specific normal database and a quantitative
assessment of regional and global left ventricular systolic
function using our counts-based gated SPECT method
(17,18).
For the purposes of this study, studies were classified as
normal or abnormal according to the absence or presence of
focal perfusion defects. Studies interpreted as “probably
normal” were grouped with the normal studies. Abnormal
studies were subclassified according to the presence or
absence of perfusion defect reversibility. Studies with “pre-
dominantly fixed” (but minimally reversible) perfusion de-
fects were classified as reversible.
Clinical variables. Three clinical variables were prospec-
tively selected as likely predictors of cardiac events based on
Abbreviations and Acronyms
CAD  coronary artery disease
ECG  electrocardiogram
MI  myocardial infarction
SPECT  single-photon emission computed
tomography/tomographic
99mTc  technetium-99m
%MAPHR  percentage of maximum age-predicted
heart rate
Table 1. Study Population (n  308)
n (%)
Age (yrs) 62 (54, 69)
Women 166 (54)
Obstructive lung disease 241 (79.3)
Theophylline or caffeine use 54 (17.8)
Height (in.) 66.5 (63, 69)
Weight (lbs) 190 (159, 227)
Prior myocardial infarction 93 (31)
Prior surgical revascularization 24 (7.9)
Prior percutaneous revascularization 26 (8.6)
Hypertension 148 (48.7)
Diabetes mellitus 89 (29.3)
Hypercholesterolemia 70 (23.0)
Prior or current tobacco use 150 (49.3)
Beta-blockers 27 (8.9)
Calcium antagonists 88 (28.9)
Angiotensin-converting enzyme inhibitors 79 (26.0)
Nitrates 79 (26.0)
Continuous parameters (age, height and weight) are expressed as median (1st quartile,
3rd quartile). Due to missing data, not all percentages reflect a denominator of 308
patients.




Baseline systolic arterial pressure (mm Hg) 140 (128, 160)
Peak systolic arterial pressure (mm Hg) 160 (140, 178)
Peak heart rate (beats/min) 124.5 (112, 135)
Peak %MAPHR 81 (71, 87)
Peak rate pressure product ( 1,000) 19.4 (16.7, 22.6)
Peak dobutamine dose (g/kg/min) 40 (30, 40)
Dobutamine-induced side effects n (%)




Atrial premature beats 66 (21.7)
Ventricular premature beats 150 (49.3)
Nonsustained ventricular tachycardia 8 (2.6)
ST depression  1 mm 52 (17.1)
%MAPHR  percent of maximum age-predicted heart rate (220  age); rate
pressure product  the product of heart rate (beats/min) and systolic arterial pressure
(mm Hg).
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the available literature (1,8). The variables were age, history
of prior MI (based on clinical history or diagnostic Q waves
on electrocardiogram [ECG]) and number of coronary
artery disease (CAD) risk factors (hypertension, diabetes
mellitus, dyslipidemia and present or recent tobacco use).
Follow-up. Patients were followed using mailed question-
naires, telephone interviews and review of medical records.
Follow-up was terminated at last patient contact or at the
time of the following end points: nonfatal MI (confirmed by
medical records demonstrating a rise and fall in cardiac-
specific markers in the setting of prolonged anginal chest
pain and/or ECG changes), cardiac death (sudden death in
the absence of other identified causes and confirmed by
medical records and/or death certificate), noncardiac death
(death from any other cause) or coronary revascularization
(percutaneous or surgical). For descriptive purposes, revas-
cularizations occurring 50 days after SPECT imaging
were classified as “early,” and those occurring50 days after
SPECT imaging were classified as “late.” All patients who
underwent revascularization were censored from subsequent
follow-up analysis. Cardiac events were defined as the
combined end point of cardiac death or nonfatal MI.
Statistical methods. Event-free survival patterns were an-
alyzed using the Cox proportional hazards regression model
for time-to-event data. The Wald chi-square test from this
model was used to determine the incremental prognostic
value of dobutamine 99mTc-sestamibi SPECT imaging.
Unpaired t tests were used to compare demographic data
from this study with those reported previously for exercise
99mTc-sestamibi SPECT imaging in our laboratory (1).
Continuous variables are expressed as median (1st quartile,
3rd quartile).
RESULTS
Follow-up events. Follow-up averaged 1.9 1.1 years and
was 99% complete. There were 33 cardiac events (15 cardiac
deaths and 18 nonfatal MIs) during 566.4 cumulative
patient years of follow-up, corresponding to an annual
cardiac event rate of 5.8% (Table 3). There were five early
revascularizations (three percutaneous, two surgical), all of
which occurred in patients with reversible perfusion defects.
There were eight late revascularizations (three percutane-
ous, five surgical). All eight patients had abnormal SPECT
studies, and six of eight demonstrated perfusion defect
reversibility. Overall, there was a relatively low rate of
revascularization (4.2%) and a high rate of noncardiac death
(4.8%), reflecting the significant comorbidity of the highly
selected study population.
Event rates according to scan results. Figure 1 depicts the
event-free survival after dobutamine SPECT imaging, dem-
onstrating significantly greater event-free survival for pa-
tients with normal studies (n  150) than those with
abnormal studies (n 158, p 0.001). The curves begin to
diverge early, with few cardiac events during the first year of
follow-up in patients with normal studies. In Figure 2, the
abnormal studies are segregated according to the presence or
Table 3. Follow-Up Events (n [% per year])
All Normal Abnormal
Cardiac events 33 (5.8) 7 (2.3) 26 (10.0)
Cardiac death 15 (2.6) 2 (0.7) 13 (5.0)
Nonfatal myocardial infarction 18 (3.2) 5 (1.6) 13 (5.0)
Surgical revascularization
Early (50 days) 2 (0.4) 0 2 (0.8)
Late (50 days) 5 (0.9) 0 5 (1.9)
Percutaneous revascularization
Early (50 days) 3 (0.5) 0 3 (1.1)
Late (50 days) 3 (0.5) 0 3 (1.1)
Noncardiac death 27 (4.8) 18 (5.9) 11 (4.2)
Figure 1. Event-free survival according to the dobutamine technetium-99m-sestamibi single-photon emission computed tomography (SPECT) results.
Event-free survival is significantly better in patients with normal SPECT results than it is in those with abnormal SPECT results. The curves begin to
diverge early, with relatively few cardiac events during the first year of follow-up in patients with normal SPECT results.
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absence of perfusion defect reversibility. Although event-
free survival in both subgroups was significantly reduced
relative to that in the normal group (p  0.001), there was
no significant difference in event-free survival between those
with entirely fixed defects (n  58) and those with at least
partial defect reversibility (n  100).
Dobutamine-induced ST-segment depression and car-
diac events. Patients with normal ECG responses to do-
butamine and normal SPECT imaging (n 127) had a very
favorable prognosis (p  0.0062 vs. other groups; Fig. 3),
with annual cardiac death and nonfatal MI rates of 0.4%
and 1.1%, respectively. In contrast, patients with an abnor-
mal ECG response and abnormal SPECT results (n  29)
had a poor prognosis, with annual cardiac death and
nonfatal MI rates of 7.9% and 13.2%, respectively. Patients
with discordant ECG and SPECT imaging results (n 
152) had an intermediate prognosis, with annual cardiac
death and nonfatal MI rates of 4.2% and 3.8%, respectively.
The proportional hazards model that gave rise to these
estimates assumes that the curves for the four groups do not
cross. The event-free survival was significantly and indepen-
dently (p  0.22 for interaction) associated with both ECG
(p  0.035) and SPECT (p  0.012) results.
The ECG response and SPECT results were significant
independent predictors of cardiac events even after clinical
variables (age, history of prior MI and number of CAD risk
factors) were considered, as reflected by the Wald chi-
square results determined by the Cox proportional hazards
Figure 2. Event-free survival in patients with abnormal single-photon emission computed tomography (SPECT) results segregated according to the
presence or absence of perfusion defect reversibility. Although the event-free survival is significantly reduced in both of the abnormal SPECT groups relative
to those with normal SPECT results, no significant effect of perfusion defect reversibility was observed on event-free survival.
Figure 3. Event-free survival according to the electrocardiogram (ECG) response and the single-photon emission computed tomography (SPECT) results.
The event-free survival was significantly and independently associated with both ECG (p  0.035) and SPECT (p  0.012) results. Patients with normal
ECG responses and normal SPECT results had a very favorable event-free survival (p  0.0062 vs. other groups). Patients with abnormal ECG responses
and abnormal SPECT results had a very high event rate.
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model (with and without adjusting for covariables). The
ECG response to dobutamine added incremental prognos-
tic information beyond that provided by clinical variables
alone (p  0.02). Single-photon emission computed to-
mography perfusion results add significant incremental
prognostic information beyond that provided by the com-
bination of clinical and ECG results (p  0.01).
Failure to achieve target heart rate was not a predictor of
cardiac events in our study. The percentage of maximum
age-predicted heart rate (%MAPHR) achieved was not a
significant predictor of cardiac events (p  0.84), and
including %MAPHR in the multivariable model caused no
substantive change in the Cox regression coefficients for the
ECG and SPECT results as predictors of cardiac events.
DISCUSSION
The major findings of this study were that patients referred
for dobutamine stress perfusion imaging are a high-risk
population and that dobutamine 99mTc-sestamibi SPECT
imaging is capable of risk stratification in these patients.
This study also confirms that the ECG response to dobut-
amine adds incremental prognostic information, a finding
that has not been consistently reported previously. Patients
with a normal ECG response and normal dobutamine
99mTc-sestamibi SPECT perfusion images had an annual
cardiac death and nonfatal MI rates of 0.4% and 1.1%,
respectively. This was the lowest risk group. In contrast,
patients with abnormal ECG responses and abnormal
SPECT images had very high rates of cardiac death and MI
(7.9% and 13.2%, respectively). Patients with discordant
ECG and scan findings (e.g., normal ECG response with
abnormal SPECT images) had intermediate event rates.
This study also highlights the importance of population risk
on the observed annual cardiac event rates after noninvasive
testing as discussed in the following text.
Importance of population risk on observed annual car-
diac event rates. A major strength of nuclear perfusion
imaging is the ability to identify patients at low risk for
future cardiac events. In this study, the annual cardiac event
rate in patients with normal dobutamine SPECT studies
was 2.3%, which is more than twofold higher than the event
rates (1%) reported after a normal exercise SPECT study
(1–8). Considered in isolation, this relatively high event rate
could be interpreted as clinical confirmation of an adverse
effect of dobutamine on myocardial uptake of 99mTc-
sestamibi as predicted in the canine model (15,16). How-
ever, cardiac event rates after a normal SPECT perfusion
study are determined by two factors: 1) the sensitivity of the
test for detecting CAD, and 2) the intrinsic cardiac risk of
the population studied. Cardiac event rates will tend to be
higher if the test sensitivity is low (patients with “false-
negative” results may have subsequent cardiac events) or if
the intrinsic cardiac risk of the patient population is high.
Therefore, the annual cardiac event rates in patients with
normal studies must be interpreted in the context of the
overall cardiac risk of the population studied. This is
analogous to the well-accepted principle that the predictive
values of noninvasive diagnostic testing are dependent on
the prevalence of disease in the population examined (19).
This concept is illustrated in Figure 4, which depicts the
annual cardiac event rates for patients referred for dobut-
amine stress (from this study) plotted together with the
cardiac event rates in patients referred for exercise SPECT
imaging at our institution (1). Excellent risk stratification is
achieved with exercise and dobutamine, as reflected by a
roughly fivefold differential in cardiac event rates between
Figure 4. The impact of population risk on the annual cardiac event rates after single-photon emission computed tomography (SPECT) perfusion imaging.
Excellent risk stratification is achieved with both exercise and dobutamine SPECT imaging as reflected by a roughly fivefold differential in event rates
between patients with normal and abnormal SPECT results. However, regardless of SPECT results, event rates are higher in patients referred for
dobutamine stress than they are in those referred for exercise stress, reflecting the higher intrinsic cardiac risk in patients referred for dobutamine perfusion
imaging.
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patients with normal and abnormal SPECT results (0.8%
vs. 5.4% for exercise and 2.3% vs. 10.0% for dobutamine,
respectively). However, regardless of the SPECT results,
the cardiac event rates are higher in patients referred for
dobutamine stress, reflecting the higher intrinsic cardiac risk
of the population referred for dobutamine stress (event rate
of 5.8% vs. 2.2% for patients referred for exercise). Patients
with “abnormal” results on exercise 99mTc-sestamibi SPECT
imaging have a similar annual cardiac event rate (5.4%) to
patients who are simply “referred” for dobutamine SPECT
imaging (5.8%).
The impact of population risk on annual event rates was
also evident in the work of Hachamovitch et al. (8). Event
rates were nearly twofold higher in patients referred for
adenosine SPECT imaging than they were in patients
referred for exercise SPECT imaging, reflecting the higher
intrinsic cardiac risk in patients referred for adenosine stress.
An imaging test will only provide “risk stratification” (sep-
aration of patients into higher and lower risk groups). The
absolute cardiac event rates will be determined by the
intrinsic cardiac risk of the population.
Comparison with experimental findings in the canine
model (prognostic importance of fixed defects). Two
independent groups of investigators have recently reported
that the myocardial uptake of 99mTc-sestamibi is attenuated
by dobutamine stress in experiments performed using a
canine model of coronary artery stenosis (15,16). These
experimental findings would suggest that dobutamine
99mTc-sestamibi SPECT imaging might be relatively insen-
sitive for the detection of mild-to-moderate coronary artery
stenoses. At first glance, the excellent risk stratification
achieved with dobutamine 99mTc-sestamibi SPECT imag-
ing in this study might appear to contradict these canine
experiments.
However, there are plausible explanations for the appar-
ent discrepancy between the canine experiments and this
clinical study. First, in the canine model, a single coronary
stenosis is created that reduces flow reserve without reduc-
ing resting flow (15), which is clinically analogous to the
patient with a moderate single-vessel stenosis without prior
MI. In this study, 93 patients (31%) had a history of prior
MI. In patients with prior MI, the resting SPECT perfu-
sion image is abnormal; the diagnosis of CAD can be made
on the basis of the resting image alone, and the predicted
attenuation of 99mTc-sestamibi uptake by dobutamine stress
is “prognostically irrelevant.” An underestimation of stress
perfusion defect severity (as predicted by the canine exper-
iments) would not alter the correct classification of the study
as “abnormal” on the basis of a fixed perfusion defect. In
support of this hypothesis, we noted that resting images
were abnormal in the majority of patients classified as
having abnormal SPECT studies (all patients with fixed
defects by definition and 90% of patients with “reversible”
defects had at least some degree of associated fixed defect).
Secondly, in some cases the stress perfusion defect severity
may have been artifactually enhanced by persistent regional
myocardial dysfunction during post-stress image acquisition
(15,20). Dobutamine-induced myocardial stunning has re-
cently been observed in the canine model (15). Finally, it is
possible that the interaction between dobutamine and
99mTc-sestamibi is unique to the canine species and does
not occur in humans, although the canine species has proved
to be a reliable predictor of human radionuclide tracer
kinetics in the past.
ECG response to dobutamine. Dobutamine-induced ST-
segment depression has been reported to have a sensitivity
of 18% to 28% for detecting CAD (21–23), a sensitivity that
is inferior to that provided by 99mTc-sestamibi SPECT
perfusion imaging or echocardiography during dobutamine
stress (22).
However, in this study, the ECG response to dobutamine
provided significant incremental prognostic information
beyond that provided by standard clinical variables. The
prognostic information provided by the ECG response was
independent of the SPECT imaging results. Of particular
clinical relevance is the finding that a low-risk group could
be identified on the basis of a concordantly normal ECG
response and normal SPECT result. Further studies are
needed to clarify the role of the ECG response to dobut-
amine in risk assessment and clinical decision making.
Study limitations. Our results should be extrapolated with
caution to other laboratories and other patient populations.
As mentioned previously, we tend to reserve dobutamine
stress for patients with contraindications to exercise and
vasodilator stressors. The annual cardiac event rates may
differ if dobutamine 99mTc-sestamibi SPECT imaging is
used more liberally, such as in patient populations without
contraindications to exercise or vasodilators.
Attenuation correction of SPECT perfusion images was
not utilized in our study, and gated SPECT imaging was
used in only 58% of patients. It is possible that the
prognostic value of dobutamine 99mTc-sestamibi SPECT
could be further enhanced by the routine application of
these techniques.
Our relatively small population size prevented analysis of
the cardiac event rates in patients with abnormal studies
according to the extent and severity of perfusion abnormal-
ities. Larger studies would be necessary to define the impact
of perfusion defect extent and severity on event-free sur-
vival.
The single-day, rest-stress imaging protocol may have
resulted in a slight underestimation of stress perfusion
defect severity due to contamination of stress tracer distri-
bution by residual tracer activity from the resting injection.
However, despite this theoretic limitation, the rest-stress
imaging protocol is widely used, and our results are, there-
fore, relevant to current clinical practice.
Clinical implications. Despite the theoretic potential for
underestimation of coronary stenoses, dobutamine 99mTc-
sestamibi SPECT myocardial perfusion imaging is capable
of cardiac risk stratification in high-risk patients with
contraindications to exercise and vasodilator stressors.
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